Department of HUMAN SERVICES

Iowa Medicaid Drug Utilization Review (DUR) Commission

August 3, 2022

Location: **Teleconference** (Due to Federal PHE Declaration for the COVID-19 Pandemic)
Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:
https://changehealthcare.webex.com/changehealthcare/j.php?MTID=m3a69055bb788f8cba8ce4f982dd28e95
Dial In: 1-844-245-7693
Meeting Number: 2537 485 5449
Meeting Password: 9SnkdrqMF22

Final Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
2. Commission Business
    a) Approval of the Minutes
    b) May 2022 DUR Recommendation Letter to DHS
    c) April 2022 P&T Committee Recommendations
    d) Annual Chair & Vice Chair Elections
    e) Annual Conflict of Interest Disclosure
    f) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Prevalence Report Summaries
    a) Amerigroup
    b) Iowa Total Care
    c) Fee-for-Service
    d) Comparative Summary
5. Public Comment* (Complete Speaker Conflict of Interest Disclosure Form)
    - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure. Five (5) minute maximum limit.
    - Written - Must submit written comments and a completed conflict of interest disclosure.
    - Reference complete public comment policy here.
    - **All submissions must be received no later than 4:30 p.m. CT July 27, 2022.**
    - Send to info@iadur.org ***Indicate in email if providing written comment or verbal comment***.
6. Retrospective DUR

a) Data Presentation(s)
    i. High Dose Opioid (> 90 MME) without Opioid Reversal Agent
    ii. Opioid plus Buprenorphine for OUD
b) Proposal(s)
    i. LABA without ICS in Asthma
    ii. Concurrent Use of Opioids and Sedatives
c) Duplicate Therapy with Opioids - Discussion
d) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR
    a) Initial Days' Supply Limit – Benzodiazepines – Second Review
    b) Benzodiazepine Cumulative Quantity Limit – Second Review
    c) Short-Acting Beta Agonist Quantity Limit – Second Review
8. Break (10 minutes)
9. Prior Authorization
    a) Sedative/Hypnotics, Non-Benzodiazepine – Initial Review
    b) Vericiguat (Verquvo) – Initial Review
    c) Maralixibat (Livmarli) – Initial Review
    d) Alpelisib (Vijoice) – Initial Review
    e) Mavacamten (Camzyos) – Initial Review
    f) Dupilumab (Dupixent) – Initial Review
    g) Viloxazine (Qelbree) – Initial Review
    h) CNS Stimulants and Atomoxetine – Initial Review
    i) Tasimelteon (Hetlioz) – Second Review
    j) Janus Kinase Inhibitors – Second Review
    k) Tralokinumab-Idrm (Adbry) – Second Review
    l) Crisaborole (Eucrisa) – Second Review
    m) Extended-Release Formulations – Second Review
    n) Non-Preferred Drug – Second Review
    o) Biologicals for Hidradenitis Suppurativa – Second Review
    p) Ophthalmic Agents for Presbyopia – Second Review
10. Miscellaneous
    a) DUR Digest Vol. 34, No. 2 – Second Review
    b) MedWatch

    FDA Approves Novel, Dual-Targeted Treatment for Type 2 Diabetes

    FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    FDA Approves First Systemic Treatment for Alopecia Areata
11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product

or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a conflict of interest disclosure. Completed forms must be provided to DUR staff at least one week prior to the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

Next Meeting
November 2, 2022
Location TBD